L&K Biomed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
L&K Biomed makes spinal implants, metal screws, plates, and cages surgically inserted into the spine to stabilize or correct conditions such as degeneration, stenosis, fractures, and scoliosis.
Its products are used by orthopedic and neurosurgeons and fall into the highest-risk regulated category for implantable medical devices in Korea. Listed on KOSDAQ, Korea's tech and small-cap board, the company covers the full product range for spinal surgery, spanning both cervical (neck) and thoracolumbar (mid-to-lower back) applications.
Summary is AI-generated and may contain errors · figures from DART filings
L&K Biomed in five facts
What does L&K Biomed do?
L&K Biomed makes spinal implants, metal screws, plates, and cages surgically inserted into the spine to stabilize or correct conditions such as degeneration, stenosis, fractures, and scoliosis.
Where is L&K Biomed listed and in which sector?
L&K Biomed (Korean name: 엘앤케이바이오) trades under KRX code 156100 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is L&K Biomed?
Its market capitalisation was US$112.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were L&K Biomed's latest annual revenue and operating profit?
For fiscal year 2025, L&K Biomed reported revenue of US$29.4M, operating profit of US$539.7K and a net loss of US$12.7M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 7.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 16
- [Amended] Half-year report (2026.06)Sep 30
- Conversion price adjustmentSep 9
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
L&K Biomed reported consolidated results for FY2025: revenue of US$27M (+7.8% year on year), operating profit of US$459K (−78.5% year on year) and a net loss of US$11.7M (from a profit a year earlier).
Earnings · Feb 19 - Material event report (decision to sell own convertible bonds)Capital raise · Jan 27
- Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Jan 22
- Material event report (convertible bonds)Capital raise · Jan 9